DREAM is a Ca2+-regulated transcriptional repressor

Area of Science:

• Molecular Biology
• Neuroscience
• Genetics

Background:

• Intracellular calcium ion (Ca2+) fluxes are critical regulators of gene expression.
• While Ca2+-regulated kinases and phosphatases are known to modulate transcription factors, direct nuclear Ca2+ effectors remain unidentified.
• The human prodynorphin gene, crucial for memory and pain, is regulated by a silencer sequence (DRE).

Purpose of the Study:

• To identify direct nuclear Ca2+-binding proteins involved in gene expression regulation.
• To characterize a novel transcriptional repressor that responds to Ca2+.
• To investigate the role of this repressor in controlling the expression of specific genes.

Main Methods:

• Isolation and characterization of a novel Ca2+-binding protein, DREAM (DRE-antagonist modulator).
• Analysis of DREAM's DNA-binding activity to the downstream regulatory element (DRE).
• Assessment of DREAM's transcriptional repressor function in response to Ca2+ stimulation and mutations in its Ca2+-binding domains (EF-hands).
• Evaluation of DREAM's effect on prodynorphin and c-fos gene promoters.

Main Results:

• DREAM was identified as a transcriptional repressor that specifically binds to the DRE sequence.
• DREAM possesses four EF-hand Ca2+-binding domains.
• Ca2+ stimulation inhibits DREAM's DNA-binding ability and repressor function.
• Mutations in the EF-hand domains abolish DREAM's Ca2+-dependent regulation.
• DREAM represses transcription from both the prodynorphin and c-fos promoters.

Conclusions:

• DREAM is the first identified Ca2+-binding protein functioning as a direct DNA-binding transcriptional regulator.
• DREAM mediates Ca2+-dependent gene repression, linking calcium signaling to transcriptional control.
• This discovery provides a new mechanism for how calcium ions influence gene expression, particularly in genes related to neuronal function and response.